|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paulo Lino, PhD, and João Henriques discuss the main development goals and present a framework for a streamlined development of amorphous solid dispersion formulations by spray drying.
|
|
|
Andrew Leber, PhD, Raquel Hontecillas, PhD, and Josep Bassaganya-Riera, PhD, say current IBD therapeutics have mediocre efficacy, poor maintenance of response, and damaging side effects, including cancer, infection, and death, resulting in an unmet clinical need for safer and more effective oral therapeutics.
|
|
|
Jeff Browne, PhD, and Ronak Savla, PharmD, PhD, believe given the accelerated timelines associated with expedited programs, lipid-based drug formulations, encapsulated in softgel capsules, provide an attractive option for addressing the challenges facing formulators.
|
|
|
Hillel Cohen, PhD, outlines the evolution of biosimilar approvals and describes the process of analytical and clinical testing followed in the development of a biosimilar, with use of data from the scientific literature.
|
|
|
Elvin Thalund, MS, and Craig Morgan say the emphasis on quality is everywhere, but in particular, the study startup portion of clinical trials is a particular hotspot, as it is pivotal to improving study conduct overall.
|
|
|
|
|
|
|
|
|

Backed by over 85 years of experience in parenterals, Baxter’s BioPharma Solutions (BPS) business collaborates with pharmaceutical companies to support commercialization objectives for their molecules. BPS is a premier CMO with a focus on injectable pharmaceutical manufacturing designed to meet complex and traditional sterile manufacturing challenges with confidence of delivery, service, and integrity. BPS can support your pharmaceutical needs with a broad portfolio of sterile fill/finish production capabilities, and our reputation is built on the high-quality products we manufacture for our clients in a cGMP environment. Click here for more.
|
|
|
|
|
|
 |
|
Protalix BioTherapeutics, Inc. and its development and commercialization partner, Chiesi Farmaceutici S.p.A. recently announced that they have completed a successful Type B Pre-Biologics License Application (BLA) meeting with the US FDA regarding….
|
|
 |
|
Seelos Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation to its new, investigational intranasal racemic ketamine program, SLS-002, for the treatment of…..
|
|
 |
|
Cytel Inc. recently announced that it has acquired MTEK Sciences to further expand its advanced real-world analytics (RWA) capabilities….
|
|
 |
|
Pharma and biotech companies, both large and small, have high expectations for their new molecules they have in development. Even the smallest of details can impact the eventual success or failure of their product…..
|
|
|
|
|
Upcoming eNewsletter Features:
November 27 – Injection Devices
December 4 – Capsules
|
|
|
|
|
|
|
|